SINGAPORE, Dec. 29, 2025 /PRNewswire/ — Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, today announced the official opening of its second clinic, Assure Family Clinic Woodlands. This expansion marks the next phase in the Group’s mission to make quality and comprehensive healthcare more accessible to families and individuals.

Located in the heart of Woodlands at 132 Marsiling Rise, the new clinic extends Assure Healthcare Holdings’ footprint beyond its first location in Bukit Merah. The clinic will provide residents in northern Singapore with convenient access to general consultations, chronic disease management, vaccinations, preventive health screenings, and minor procedures.

“The launch of the Assure Family Clinic in Woodlands marks an important milestone in our growth journey,” said Dr Joanne Koay, Chief Medical Officer of Assure Healthcare Holdings. “Our goal is to bring compassionate, reliable care closer to the communities we serve, giving families peace of mind knowing that accessible healthcare is always within reach.”

Leading the Woodlands clinic is Dr Vikneswaran V. Paranjothy, a General Practitioner with specialised training in occupational medicine, dermatology, aesthetics, and andrology. With extensive experience in workplace health, preventive care, and minor procedures, Dr Vik takes a holistic and patient-centred approach to serving the community.

“Healthcare is a cornerstone of SingWealth Holdings’ vision to provide holistic solutions across health, wealth, and legacy planning,” added Jeffrey Chow, Executive Director and Group CEO of SingWealth Holdings. “The expansion reflects our strong commitment to supporting the well-being of Woodlands’ residents, as well as our SingWealth’s clients and their families at every stage of life. This includes critical planning tools such as the Advance Medical Directive, which empower individuals to make informed decisions about their future care and uphold their personal values with dignity.”

For more information about the clinic’s services or to book an appointment, please visit assureclinic.sg.

About Assure Healthcare Holdings

Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, is dedicated to delivering accessible, patient-centered care through a growing network of medical practices. Its comprehensive suite of services includes General Practitioner (GP) consultations, preventive medical care, aesthetic treatments, and Advance Medical Directive (AMD) support.

With a commitment to enhancing community healthcare, Assure Healthcare Holdings provides quality care and trusted medical guidance to support individuals and families at every stage of life.

For more information, visit assureclinic.sg. 

About SingWealth Holdings

SingWealth Holdings is a dynamic holding company with a strategic presence across Singapore, Thailand, Malaysia, China, and Hong Kong. Through its subsidiaries, it delivers comprehensive financial advisory, insurance brokerage, and estate planning solutions tailored to the evolving needs of individuals and businesses.

Its financial services portfolio comprises PFPFA Pte Ltd (Singapore), PFPFA HK Ltd (Hong Kong), and PFPFA (Malaysia) Sdn Bhd, providing trusted financial expertise and strategic advisory solutions to clients in their respective markets.

SingWealth Holdings also supports PFP Legacy entities across the region, catering to the needs of emerging affluent clients with wills and trust services in Singapore, Thailand, Malaysia, Hong Kong, and Shanghai. These services are designed to safeguard wealth and ensure smooth succession planning for individuals and families.

In Singapore, SingWealth Holdings operates Assure Healthcare Holdings, a healthcare brand committed to accessible, patient-centered care. Assure Healthcare offers general practitioner services, preventive medical care, aesthetic treatments, and Advance Medical Directive (AMD) support.

Driven by innovation and excellence, SingWealth Holdings continues to empower communities across Asia with financial stability and enhanced well-being.

For more information, visit https://singwealthholdings.com.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. (“Lannacheng”). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs).

Compared with conventional radiotherapy, RDCs utilize tumor antigen–specific ligands to deliver radionuclides directly to tumor lesions for targeted radiotherapy, thereby effectively reducing damage to surrounding healthy tissues. In contrast to antibody–drug conjugates (ADCs), the radionuclides in RDCs can also exert cytotoxic effects on neighboring tumor cells and the tumor microenvironment, even if those cells do not express the target antigen. This mechanism offers a potential advantage in overcoming tumor heterogeneity and drug resistance. In addition, this technology holds the potential to achieve theranostics—integrating both diagnosis and treatment.

With its advanced technology platforms and deep expertise, Harbour BioMed has built a solid foundation in antibody discovery and development. The company’s proprietary Harbour Mice^® platform enables the generation of fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats, eliminating the need for additional engineering or humanization. The HCAb technology, in particular, produces unique, fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapeutics. In the development of RDCs, fully human antibodies—characterized by low immunogenicity, superior tissue penetration, and high specificity and stability—can significantly enhance the efficiency of targeted delivery, thereby improving therapeutic efficacy while effectively reducing drug-related toxicity and side effects.

Founded in 2021, Lannacheng is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of integrated theranostic radiopharmaceuticals for oncology. The company’s R&D engine, enhanced by its proprietary pharmacokinetic optimization and dual-targeting drug development platforms, combines target validation, radioisotope selection, and linker design to improve pharmacokinetic profiles and advance the development of dual-targeting radiopharmaceutical candidates. Its strengths are further solidified through end-to-end integration of capabilities supported by its controlling shareholder, Dongcheng Biochem, including R&D resources, a stable supply of radioisotopes, and a GMP production facility currently under construction in Yantai. Together, these elements ensure a sustainable, scalable, and rapidly innovating radiopharmaceutical pipeline.

Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented: “We are very pleased to establish a long-term strategic collaboration with Lannacheng to jointly advance the development of next-generation RDCs. Harbour BioMed is committed to providing efficient and highly differentiated antibody solutions for innovative therapies through our globally leading Harbour Mice^® fully human antibody platform. This collaboration will deeply integrate Harbour BioMed’s expertise in antibody discovery with Lannacheng’s strengths in radiopharmaceutical R&D and commercialization, accelerating the development of more precise, effective and safe cancer therapies and bringing new hope to patients worldwide.”

Wu Xiaoming, General Manager of Lannacheng, stated: “We are delighted to establish a long-term strategic collaboration with Harbour BioMed to jointly advance the R&D and translation of next-generation radiopharmaceuticals. Lannacheng is committed to leveraging our systematic radiopharmaceutical technology platform, comprehensive industrial capabilities, and global collaboration network to provide efficient, innovative, and differentiated integrated solutions for tumor diagnosis and treatment. This collaboration will fully combine Lannacheng’s strengths in radiopharmaceutical R&D and commercialization and Harbour BioMed’s deep expertise in antibody discovery. Together, we aim to accelerate the development of more precise, effective, and safe cancer treatment therapies, bringing new hope to patients worldwide.”

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice^®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICA™) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice^®, HBICE^®, and HBICA™ with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

About Yantai Lannacheng Biotechnology Co., Ltd.

Founded in 2021, Lannacheng is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of integrated theranostic radiopharmaceuticals for oncology. The company’s R&D engine, enhanced by its proprietary pharmacokinetic optimization and dual-targeting drug development platforms, combines target validation, radioisotope selection, and linker design to improve pharmacokinetic profiles and advance the development of dual-targeting radiopharmaceutical candidates. Its strengths are further solidified through end-to-end integration of capabilities supported by its controlling shareholder, Dongcheng Biochem, including R&D resources, a stable supply of radioisotopes, and a GMP production facility currently under construction in Yantai. Together, these elements ensure a sustainable, scalable, and rapidly innovating radiopharmaceutical pipeline.

LIUZHOU, China, Dec. 29, 2025 /PRNewswire/ — Last month, LiuGong (000528.SZ) officially unveiled its new E-Intelligence brand at the 2025 Global Dealer Conference and 11•26 Global Customer Day held in Liuzhou. The global launch marks a major milestone in LiuGong’s green transformation and its next phase of sustainable development.

Centered on the brand manifesto “FORWARD GREEN, POWER THE EXTREMES,” the launch underscores LiuGong’s dual commitment: to continuously advance the construction machinery industry toward a more sustainable future, and to deliver reliable, powerful productivity for customers—even under the most extreme operating conditions—through electrification and intelligent technologies.

This brand upgrade signals LiuGong’s strategic transition from a traditional equipment manufacturer to a full-lifecycle provider of green productivity solutions.

Technology Innovation: Multiple Paths Toward “Powering the Extremes”

In its electrification journey, LiuGong does not pursue a single technological path. Instead, the company focuses on real-world applications, building a diversified and reliable portfolio of solutions. From pure electric to hybrid systems, from tethered power to fast battery swapping, LiuGong delivers highly customized designs to help customers achieve the optimal balance between productivity and total cost of ownership across different environments and operating conditions.

Extreme Cold (-30°C): Remote pre-heating systems and low-temperature battery adaptation technologies significantly reduce cold-start time and enhance operational stability in sub-zero conditions.

Extreme Heat (+50°C): Advanced thermal management systems, reinforced cooling solutions, and heat-resistant materials ensure stable performance of batteries and electronic controls during continuous heavy-load operations.

Special Operating Conditions: To address challenges such as high-altitude environments and corrosive chemical settings, LiuGong applies enhanced cooling designs, anti-corrosion components, and IP67-rated battery protection to safeguard core productivity.

Building the Future Ecosystem: From Equipment to Intelligent Operations

For LiuGong, electrification is only the beginning. The company’s long-term vision is to establish an intelligent ecosystem that integrates energy, equipment, data, and operations. Built on green energy infrastructure, intelligent operation platforms, and data-driven optimization, this ecosystem enables coordinated equipment operation, efficient energy utilization, and continuous operational improvement. Through services such as battery recycling and battery banking, LiuGong aims to create a sustainable closed-loop system covering the entire product lifecycle.

“2026 Green Alliance Global Tour” Officially Launched

During the launch event, LiuGong officially announced the start of the “2026 Green Alliance Global Tour.” Partnering with 9 global dealers and customer partners, the initiative will channel selected green business achievements into ongoing global public welfare projects. The LiuGong Green Alliance has already delivered tangible impact in multiple regions, including clean drinking water projects in Africa and central kitchen construction in Indonesia, improving living and learning conditions for local communities and schools. The launch ceremony was jointly witnessed by Mr. Luo Guobing, President of LiuGong, representatives of global partners, and diplomatic envoys from multiple countries. Looking ahead, LiuGong will invite more partners to join the Green Alliance, bringing the vision of “Forward Green” to communities worldwide and jointly advancing a greener, more sustainable future.

SINGAPORE, Dec. 29, 2025 /PRNewswire/ — In anticipation of the upcoming Chinese New Year (CNY), Little Flower Hut, an online flower shop in Singapore, has announced a new range of hampers that embrace inclusivity while honouring the spirit of the festive season. The CNY gift set introduces halal and vegetarian options, catering to the diverse dietary preferences and cultural values of Singapore’s multicultural community.

Going Beyond Traditional CNY Gifting

Chinese New Year has long been a season for exchanging symbolic treats and gifts that represent prosperity, luck, and happiness. However, many traditional hampers often contain items unsuitable for recipients with specific dietary restrictions. Recognising this gap, Little Flower Hut set out to “go beyond the traditional” by curating and launching a series of inclusive hampers designed to let everyone share in the joy of giving.

“Our goal was to create CNY gift sets that bring people together, regardless of dietary needs or beliefs,” said a spokesperson for Little Flower Hut. “The new line allows customers to share festive blessings without worry, while still enjoying the same sense of abundance and celebration that Chinese New Year is known for.”

A Modern Take on Classic Festive Gifting

The new CNY gift sets feature an array of premium goodies, snacks, and wellness items suitable for families, colleagues, and corporate partners. Customers can choose from halal CNY hamper selections containing products sourced from trusted suppliers, as well as vegetarian CNY hampers that focus on natural, plant-based ingredients and wholesome snacks. Each hamper is presented in a contemporary festive design that reflects both tradition and modern elegance.

Little Flower Hut’s design team ensures that presentation remains a key focus. Every hamper is carefully assembled to balance aesthetics and symbolism, from auspicious colour palettes to the thoughtful arrangement of items such as tonics, assorted fruits, and festive treats. Whether purchased for loved ones or business associates, the new product line embodies a sense of refinement and consideration.

Bringing Fresh Blooms and Prosperity Together

In addition to the new range of CNY gift sets, Little Flower Hut continues to offer an extensive collection of festive floral arrangements designed to complement the season’s joyful atmosphere. Customers can pair Chinese New Year hampers with symbolic flowers such as orchids, peonies, or pussy willows, all of which represent prosperity, growth, and renewal in Chinese tradition. With same-day and one-hour express CNY hamper delivery options available across Singapore, Little Flower Hut ensures that every festive greeting arrives fresh and right on time.

To explore the full range of hampers and floral arrangements, visit Little Flower Hut’s website.

About Little Flower Hut

Little Flower Hut is an online florist in Singapore that offers a full range of arrangements for every occasion, from birthdays, anniversaries, and graduations to festive celebrations like Christmas, Chinese New Year, and Valentine’s Day. Each bouquet is hand-crafted with precision and passion, using only the freshest blooms available. With islandwide same-day delivery (including express options within an hour), Little Flower Hut makes it easy for customers to send or receive flowers whenever and wherever they wish.

SINGAPORE and TOKYO, Dec. 29, 2025 /PRNewswire/ — CYFIRMA, a global leader in preemptive and predictive cybersecurity, today released its 2025 impact recap for the DeCYFIR platform. The report highlights tangible, measurable results in empowering organizations worldwide to anticipate, disrupt, and neutralize emerging cyber threats before they materialize.

Powered by its revolutionary 9-pillar AI architecture, DeCYFIR has transformed cybersecurity from reactive defense to proactive preemption. Throughout 2025, the platform delivered early warnings weeks or months in advance, prioritized critical vulnerabilities, reduced digital and supply-chain exposures, and enhanced team readiness through adaptive, threat-led training. The DeCYFIR delivers comprehensive external threat visibility, intelligence correlation, risk prioritization, and active deception capabilities.

With a global presence, DeCYFIR secures enterprises across every major industry, deploying more than 900 enterprise licenses worldwide.

DeCYFIR is trusted by nations and critical sectors alike. Over 20% of its clients are federal agencies and governments, with additional representation including 20% in technology, 12% in manufacturing, 8% in finance, and more.

The company’s early warning capabilities have delivered billions of dollars in value, successfully defending US$5.5 billion in client’s tangible and intangible financial impact from potential threats.

DeCYFIR proactive defense operates at unprecedented scale, stopping attacks before they materialize:

• 7,158 early warnings issued
• 27,582 top-level domains protected
• 1.8 million attack surfaces managed
• 2.1 million cyber risks neutralized

Powered by advanced AI, DeCYFIR achieves superior detection speed, productivity gains, and deepfake defense. More than 14,600 users are empowered through the Ask DeCYFIR AI Agent, while 6,456 deepfakes have been identified and mitigated.

DeCYFIR strengthens extended ecosystems by securing ironclad supply chains, managing and protecting 82,000 third-party entities.

By transforming humans into active defenders, DeCYFIR has delivered 83 intelligence-led cyber education programs.

The platform operates 16 industry-specific deception environments, using tailored decoys to trap attackers effectively.

Staying ahead of every threat, DeCYFIR’s predictive intelligence tracks more than 5,235 threat actors, monitors over 7,298 hacking campaigns and identified unique original 682,000 threat indicators.

“DeCYFIR’s 2025 advancements in preemptive external threat landscape management, predictive threat intelligence, elevation of human as cyber sensor, and deception technology demonstrate AI-driven cybersecurity delivers tangible protection and massive value,” said Kumar Ritesh, Founder, CEO and Chairman of CYFIRMA. “We remain committed to outpacing adversaries and safeguarding our clients’ most critical assets.”

For more information, visit www.cyfirma.com.

About DeCYFIR

CYFIRMA is a global leader in preemptive external threat landscape management, enabling organizations to predict and prevent cyberattacks through its AI-powered intelligence platform. By integrating nine pillars of external threat management including Attack Surface Discovery, Vulnerability Intelligence, Brand & Digital Risk Management, Third-Party Risk, Situational Awareness, Predictive Threat Intelligence, Threat Adaptive Awareness, and Sector-Tailored Deception Intelligence, CYFIRMA shifts cybersecurity from reactive to predictive. The platform delivers early warnings, personalized insights, and actionable intelligence from a hacker’s perspective, helping reduce cyber risk and costs through threat prioritization, contextual decision-making, improved visibility, and stronger operational resilience. CYFIRMA serves Fortune 500 companies and national agencies and is headquartered in Singapore with offices across APAC, the US, and EMEA.